Lost in translation : barriers to incentives for translational research in medical sciences / editors, Rakesh Srivastava, Wojciech Maksymowicz, Wlodek Lopaczynski ; contributors Edyta Adamska [and eighty seven others].

Format:

Book

Contributor:

Srivastava, Rakesh K., editor of compilation.

Maksymowicz, Wojciech, editor of compilation.

Lopaczynski, Wlodek, editor of compilation.

Adamska, Edyta, contributor.

Standardized Title:

Lost in translation (Srivastava, Maksymowicz, and Lopaczynski)

Language:

English

Subjects (All):

Medicine--Research.

Medicine.

Translational Research, Biomedical.

Medical Subjects:

Translational Research, Biomedical.

Physical Description:

1 online resource (766 p.)

Place of Publication:

Singapore : World Scientific, 2014.

Language Note:

English

Summary:

This book is all about the definition and finding ways to prioritize and accelerate translation research in biomedical sciences and rapidly turning new knowledge into first-in-human studies. It represents an effort to bring together scientists active in various areas of translational research to share science and, hopefully, generate new ideas and potential collaborations. The book provides a comprehensive overview of translational work that includes significant discoveries and pioneering contributions, e.g., in immunology, gene therapy, stem cells and population sciences. It may be used as an

Contents:

Foreword; From the Editors; Contents; List of Contributors; I. BARRIERS TO INCENTIVES FOR TRANSLATIONAL RESEARCH; 1. Translational Research: Lost in Complexity; INTRODUCTION; WHAT IS BIOLOGICAL COMPLEXITY?; Analytical Approaches; Hierarchical Levels; Self-organization; THE COMPLEXITY OF NETWORKS IN CELLS AND ORGANISMS; Systems Biology; Disease Networks; Equilibrium States and Attractors; Complex Responses in Cells and Organisms; SERENDIPITY, A CRUCIAL FACTOR IN BIOMEDICAL RESEARCH; THE LIMITS OF TRANSLATIONAL RESEARCH; REFERENCES; 2. Methylation, Methionine and Metaphors

2.1. INTRODUCTION-WHAT IS TRANSLATION?2.2. BUT IS THIS THE WHOLE STORY?; 2.3. THE BENCH SCIENTIST VIEW; 2.3.1. Histone Modifications; 2.3.2. DNA Methylation; 2.3.3. Noncoding RNAs; 2.3.4. Mitotic Bookmarking; 2.3.5. Dreams of Clinical Applications; 2.4. THE CLINICIAN INVESTIGATOR VIEW; 2.4.1. The Necessity of Methionine; 2.4.2. The Hope for Gene Reactivation; 2.4.3. Dreams of Cancer Cure; 2.5. WHAT IS LOST IN TRANSLATION?; 2.6. CONCLUSIONS; REFERENCES; II. INTEGRATING EMERGING SCIENCE INTO CLINICAL PRACTICE; 3. Integrating Emerging Science into Clinical Medicine; 3.1. INTRODUCTION

3.2. EFFORTS TO DEFINE TRANSLATIONAL RESEARCH, SCIENCE AND MEDICINE3.3. TRANSLATIONAL TRIALS; 3.4. CLINICAL APPLICATIONS; 3.4.1. Oncology; 3.4.2. Translational Genomics (Genome Medicine and Genome Biology); 3.4.3. Stem Cell Research and Therapy; 3.4.4. Immunosuppression; 3.4.5. Pharmacogenomics; 3.4.6. Biomarkers; 3.4.7. The Breast; 3.4.8. Gastrointestinal/Colon Cancer; 3.4.9. The Heart; 3.4.10. Critical Care; 3.4.11. Alzheimer's Research and Therapy; 3.4.12. Multiple Sclerosis; 3.4.13. Arthritis Research and Therapy; 3.4.14. Cystic Fibrosis; 3.5. THE FUTURE; 3.6. CONCLUSIONS; REFERENCES

4. Clinical Implications of miRNAs in Human Diseases4.1. INTRODUCTION; 4.2. BIOGENESIS OF miRNA; 4.3. TECHNIQUES FOR DETECTION OF miRNA; 4.4. ASSOCIATION OF miRNA WITH DISEASES; 4.4.1. Neurodegenerative Diseases; 4.4.2. Cancer; 4.4.3. Kidney Diseases; 4.4.4. Cardiovascular Diseases; 4.5. METHODS FOR miRNA DELIVERY; 4.6. CHALLENGES FOR DEVELOPING miRNAs AS THERAPEUTICS; 4.7. miRNA AS BIOMARKERS; 4.8. CONCLUSION; ACKNOWLEDGMENTS; REFERENCES; 5. Integrating Emerging Science into Clinical Practice:Targeting Androgen Signaling in Castration Resistant Metastatic Prostate Cancer; 5.1. INTRODUCTION

5.2. MOLECULAR MECHANISMS UNDERLYING PROGRESSION OF CASTRATION RESISTANT PROSTATE CANCER5.3. DRUGS TARGETING ANDROGEN BIOSYNTHESIS; 5.4. DRUGS TARGETING THE ANDROGEN RECEPTOR; 5.5. CONCLUSIONS; REFERENCES; 6. Recruitment to Early Phase Cancer Clinical Trials: Barriers and Opportunities; 6.1. INTRODUCTION; 6.2. FACTORS THAT INFLUENCE PATIENT PARTICIPATION IN EARLY PHASE CANCER CLINICAL TRIALS; 6.2.1. Public Attitudes and Knowledge toward Participation in Clinical Trials; 6.2.2. Patients' Barriers and Motivators for Participation in Early Phase Cancer Clinical Trials

6.2.3. Awareness of Clinical Trials among Patients with Cancer

Notes:

Description based upon print version of record.

Includes bibliographical references at the end of each chapters and index.

Description based on print version record.

ISBN:

981-4489-07-7